Tecpar will manufacture a biopharmaceutical for South America.
In a $19-million transaction with ProMetic Life Sciences, Tecpar will locally manufacture a biopharmaceutical product for the Brazilian domestic market as well as all other South American countries.
ProMetic will manage the development of the proprietary manufacturing process that is based on technology licensed from the Biotechnology Research Institute (BRI) and the company’s own bioseparation process, which uses Mimetic Ligand™ technology.
As part of the technology transfer and licensing agreement, ProMetic has granted Tecpar exclusive rights to use the technology for the selected biopharmaceutical product. The project will involve a selected team from all parties, including scientists and engineers from ProMetic, BRI, Tecpar as well as Validapro, a Quebec-based company dedicated to fulfilling regulatory compliance needs in the pharmaceutical industry.
